You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePentosan Polysulfate
Accession NumberDB00686  (APRD01175)
TypeSmall Molecule
GroupsApproved
DescriptionA sulfated pentosyl polysaccharide with heparin-like properties. [PubChem]
Structure
Thumb
Synonyms
Pentosan sulfuric polyester
Pentosane polysulfate
Pentosani polysulfas
Pentosano polisulfato
Pentosanpolysulfat
External Identifiers
  • CB-8061
  • PZ 68
  • SP 54
  • UNII-F59P8B75R4
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Elmironcapsule, gelatin coated100 mg/1oralJanssen Pharmaceuticals, Inc.1996-09-26Not applicableUs
Elmironcapsule, gelatin coated100 mg/1oralPhysicians Total Care, Inc.2003-12-17Not applicableUs
Elmironcapsule, gelatin coated100 mg/1oralCardinal Health1996-09-26Not applicableUs
Elmironcapsule100 mgoralJanssen Inc1993-12-31Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
ComforaSwati Spentose Pvt. Ltd.
FibraseTeofarma
FibrezymBene
HemoclarSanofi Winthrop
HémoclarSanofi-Aventis
Tavan-SPSanofi-Aventis
ThrombocidBene-Chemie
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Calcium pentosan polysulfate
ThumbNot applicableDBSALT001142
Pentosan polysulfate sodium
ThumbNot applicableDBSALT000991
Categories
UNIIF59P8B75R4
CAS number37300-21-3
WeightAverage: 602.497
Monoisotopic: 601.922340398
Chemical FormulaC10H18O21S4
InChI KeyInChIKey=FCCNSUIJIOOXEZ-SJYYZXOBSA-N
InChI
InChI=1S/C10H18O21S4/c11-3-1-26-10(8(31-35(22,23)24)5(3)28-32(13,14)15)27-4-2-25-9(12)7(30-34(19,20)21)6(4)29-33(16,17)18/h3-12H,1-2H2,(H,13,14,15)(H,16,17,18)(H,19,20,21)(H,22,23,24)/t3-,4-,5+,6+,7-,8-,9-,10+/m1/s1
IUPAC Name
[(2S,3R,4S,5R)-5-hydroxy-2-{[(3R,4S,5R,6R)-6-hydroxy-4,5-bis(sulfooxy)oxan-3-yl]oxy}-4-(sulfooxy)oxan-3-yl]oxidanesulfonic acid
SMILES
O[C@@H]1CO[C@@H](O[C@@H]2CO[C@@H](O)[[email protected]](OS(O)(=O)=O)[[email protected]]2OS(O)(=O)=O)[[email protected]](OS(O)(=O)=O)[[email protected]]1OS(O)(=O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as o-glycosyl compounds. These are glycoside in which a sugar group is bonded through one carbon to another group via a O-glycosidic bond.
KingdomOrganic compounds
Super ClassOrganooxygen compounds
ClassCarbohydrates and carbohydrate conjugates
Sub ClassGlycosyl compounds
Direct ParentO-glycosyl compounds
Alternative Parents
Substituents
  • O-glycosyl compound
  • Disaccharide
  • Sulfuric acid monoester
  • Sulfuric acid ester
  • Alkyl sulfate
  • Sulfate-ester
  • Oxane
  • Organic sulfuric acid or derivatives
  • Secondary alcohol
  • Hemiacetal
  • Oxacycle
  • Organoheterocyclic compound
  • Acetal
  • Hydrocarbon derivative
  • Alcohol
  • Aliphatic heteromonocyclic compound
Molecular FrameworkAliphatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the relief of bladder pain or discomfort associated with interstitial cystitis.
PharmacodynamicsPentosan polysulfate sodium is a low molecular weight heparin-like compound. It has anticoagulant and fibrinolytic effects.
Mechanism of actionPentosan polysulfate is a polymer of xylose hydrogen sulfate and contains two sulfate groups per carbohydrate monomer. It binds Fibroblast growth factors (FGFs) as well as other heparin-binding growth factors. It has been shown to interact also with the heparin-binding site of FGFR-1. It inhibits the growth of SW13 adrenocortical cells transfected with FGF-4 and tumorigenicity of MCF-7 breast carcinoma cells transfected with FGF-1 or FGF-4.
Related Articles
AbsorptionSlow
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life4.8 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption-0.5
Blood Brain Barrier+0.8606
Caco-2 permeable-0.6462
P-glycoprotein substrateNon-substrate0.7185
P-glycoprotein inhibitor IInhibitor0.6326
P-glycoprotein inhibitor IINon-inhibitor0.9889
Renal organic cation transporterNon-inhibitor0.8869
CYP450 2C9 substrateNon-substrate0.9008
CYP450 2D6 substrateNon-substrate0.8275
CYP450 3A4 substrateNon-substrate0.6053
CYP450 1A2 substrateNon-inhibitor0.8007
CYP450 2C9 inhibitorNon-inhibitor0.8387
CYP450 2D6 inhibitorNon-inhibitor0.8982
CYP450 2C19 inhibitorNon-inhibitor0.8044
CYP450 3A4 inhibitorNon-inhibitor0.9891
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.964
Ames testNon AMES toxic0.6383
CarcinogenicityNon-carcinogens0.5703
BiodegradationNot ready biodegradable0.8772
Rat acute toxicity2.3876 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8908
hERG inhibition (predictor II)Non-inhibitor0.7929
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Ortho mcneil janssen pharmaceuticals inc
Packagers
Dosage forms
FormRouteStrength
Capsuleoral100 mg
Capsule, gelatin coatedoral100 mg/1
Prices
Unit descriptionCostUnit
Elmiron 100 mg capsule3.32USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5180715 No1993-01-192010-01-19Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-8Not Available
Predicted Properties
PropertyValueSource
Water Solubility3.49 mg/mLALOGPS
logP-2.5ALOGPS
logP-11ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)-2.9ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge-4ChemAxon
Hydrogen Acceptor Count17ChemAxon
Hydrogen Donor Count6ChemAxon
Polar Surface Area322.55 Å2ChemAxon
Rotatable Bond Count10ChemAxon
Refractivity96.38 m3·mol-1ChemAxon
Polarizability46.17 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability0ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Pandurang Balwant Deshpande, Parvenkumar Luthra, Anand Kumar Pandey, Dinesh Jayntibhai Paghdar, Phani,Sharma,Gowthamaiah Vemavarapu Govardhana, “PROCESS FOR THE PREPARATION OF PENTOSAN POLYSULFATE OR SALTS THEREOF.” U.S. Patent US20100105889, issued April 29, 2010.

US20100105889
General References
  1. Ghosh P, Smith M: Osteoarthritis, genetic and molecular mechanisms. Biogerontology. 2002;3(1-2):85-8. [PubMed:12014849 ]
External Links
ATC CodesC05BA04G04BX15
AHFS Codes
  • 92:00.00
PDB EntriesNot Available
FDA labelDownload (59.2 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AbciximabPentosan Polysulfate may increase the anticoagulant activities of Abciximab.
AceclofenacAceclofenac may increase the anticoagulant activities of Pentosan Polysulfate.
AcenocoumarolPentosan Polysulfate may increase the anticoagulant activities of Acenocoumarol.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Acetylsalicylic acid.
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Pentosan Polysulfate.
AdapaleneAdapalene may increase the anticoagulant activities of Pentosan Polysulfate.
AllylestrenolThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Allylestrenol.
AlprostadilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Alprostadil.
AlprostadilAlprostadil may increase the anticoagulant activities of Pentosan Polysulfate.
AlteplaseAlteplase may increase the anticoagulant activities of Pentosan Polysulfate.
AltrenogestThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Altrenogest.
ALX-0081ALX-0081 may increase the anticoagulant activities of Pentosan Polysulfate.
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Pentosan Polysulfate.
AnagrelideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Anagrelide.
AnagrelideAnagrelide may increase the anticoagulant activities of Pentosan Polysulfate.
AncrodPentosan Polysulfate may increase the anticoagulant activities of Ancrod.
AnistreplaseAnistreplase may increase the anticoagulant activities of Pentosan Polysulfate.
AntipyrineAntipyrine may increase the anticoagulant activities of Pentosan Polysulfate.
Antithrombin III humanPentosan Polysulfate may increase the anticoagulant activities of Antithrombin III human.
ApixabanApixaban may increase the anticoagulant activities of Pentosan Polysulfate.
ApremilastApremilast may increase the anticoagulant activities of Pentosan Polysulfate.
ArdeparinPentosan Polysulfate may increase the anticoagulant activities of Ardeparin.
ArgatrobanPentosan Polysulfate may increase the anticoagulant activities of Argatroban.
AstaxanthinAstaxanthin may increase the anticoagulant activities of Pentosan Polysulfate.
AzapropazoneAzapropazone may increase the anticoagulant activities of Pentosan Polysulfate.
AzelastineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Azelastine.
AzelastineAzelastine may increase the anticoagulant activities of Pentosan Polysulfate.
BalsalazideBalsalazide may increase the anticoagulant activities of Pentosan Polysulfate.
BatroxobinBatroxobin may increase the anticoagulant activities of Pentosan Polysulfate.
BazedoxifeneBazedoxifene may decrease the anticoagulant activities of Pentosan Polysulfate.
BecaplerminPentosan Polysulfate may increase the anticoagulant activities of Becaplermin.
BemiparinBemiparin may increase the anticoagulant activities of Pentosan Polysulfate.
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Pentosan Polysulfate.
BeraprostThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Beraprost.
BeraprostBeraprost may increase the anticoagulant activities of Pentosan Polysulfate.
BivalirudinPentosan Polysulfate may increase the anticoagulant activities of Bivalirudin.
BromfenacBromfenac may increase the anticoagulant activities of Pentosan Polysulfate.
CangrelorThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cangrelor.
CangrelorCangrelor may increase the anticoagulant activities of Pentosan Polysulfate.
CarprofenCarprofen may increase the anticoagulant activities of Pentosan Polysulfate.
CastanospermineCastanospermine may increase the anticoagulant activities of Pentosan Polysulfate.
CelecoxibCelecoxib may increase the anticoagulant activities of Pentosan Polysulfate.
CertoparinPentosan Polysulfate may increase the anticoagulant activities of Certoparin.
ChloroquineChloroquine may increase the anticoagulant activities of Pentosan Polysulfate.
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Pentosan Polysulfate.
CilostazolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Cilostazol.
CilostazolCilostazol may increase the anticoagulant activities of Pentosan Polysulfate.
Citric AcidPentosan Polysulfate may increase the anticoagulant activities of Citric Acid.
ClonixinClonixin may increase the anticoagulant activities of Pentosan Polysulfate.
ClopidogrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Clopidogrel.
ClopidogrelClopidogrel may increase the anticoagulant activities of Pentosan Polysulfate.
CollagenaseThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Collagenase.
Conjugated Equine EstrogensConjugated Equine Estrogens may decrease the anticoagulant activities of Pentosan Polysulfate.
D-LimoneneD-Limonene may increase the anticoagulant activities of Pentosan Polysulfate.
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Pentosan Polysulfate.
DalteparinPentosan Polysulfate may increase the anticoagulant activities of Dalteparin.
DanaparoidPentosan Polysulfate may increase the anticoagulant activities of Danaparoid.
DasatinibDasatinib may increase the anticoagulant activities of Pentosan Polysulfate.
DeferasiroxThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deferasirox.
DefibrotideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Defibrotide.
DefibrotideDefibrotide may increase the anticoagulant activities of Pentosan Polysulfate.
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Deoxycholic Acid.
DesirudinPentosan Polysulfate may increase the anticoagulant activities of Desirudin.
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Pentosan Polysulfate.
DesogestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Desogestrel.
DextranPentosan Polysulfate may increase the anticoagulant activities of Dextran.
Dextran 40Pentosan Polysulfate may increase the anticoagulant activities of Dextran 40.
Dextran 70Pentosan Polysulfate may increase the anticoagulant activities of Dextran 70.
Dextran 75Pentosan Polysulfate may increase the anticoagulant activities of Dextran 75.
DiclofenacDiclofenac may increase the anticoagulant activities of Pentosan Polysulfate.
DicoumarolPentosan Polysulfate may increase the anticoagulant activities of Dicoumarol.
DienestrolDienestrol may decrease the anticoagulant activities of Pentosan Polysulfate.
DienogestThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Dienogest.
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Pentosan Polysulfate.
DiflunisalDiflunisal may increase the anticoagulant activities of Pentosan Polysulfate.
DipyridamoleThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Dipyridamole.
DipyridamoleDipyridamole may increase the anticoagulant activities of Pentosan Polysulfate.
DitazoleDitazole may increase the anticoagulant activities of Pentosan Polysulfate.
DrospirenoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Drospirenone.
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Pentosan Polysulfate.
DroxicamDroxicam may increase the anticoagulant activities of Pentosan Polysulfate.
DydrogesteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Dydrogesterone.
Edetic AcidPentosan Polysulfate may increase the anticoagulant activities of Edetic Acid.
EdoxabanEdoxaban may increase the anticoagulant activities of Pentosan Polysulfate.
EnoxaparinPentosan Polysulfate may increase the anticoagulant activities of Enoxaparin.
EpinastineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epinastine.
EpinastineEpinastine may increase the anticoagulant activities of Pentosan Polysulfate.
EpirizoleEpirizole may increase the anticoagulant activities of Pentosan Polysulfate.
EpoprostenolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Epoprostenol.
EpoprostenolEpoprostenol may increase the anticoagulant activities of Pentosan Polysulfate.
EptifibatideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Eptifibatide.
EptifibatideEptifibatide may increase the anticoagulant activities of Pentosan Polysulfate.
EstradiolEstradiol may decrease the anticoagulant activities of Pentosan Polysulfate.
EstriolEstriol may decrease the anticoagulant activities of Pentosan Polysulfate.
EstroneEstrone may decrease the anticoagulant activities of Pentosan Polysulfate.
EtanerceptEtanercept may increase the anticoagulant activities of Pentosan Polysulfate.
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Pentosan Polysulfate.
Ethyl biscoumacetatePentosan Polysulfate may increase the anticoagulant activities of Ethyl biscoumacetate.
EtodolacEtodolac may increase the anticoagulant activities of Pentosan Polysulfate.
EtofenamateEtofenamate may increase the anticoagulant activities of Pentosan Polysulfate.
EtonogestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Etonogestrel.
EtoricoxibEtoricoxib may increase the anticoagulant activities of Pentosan Polysulfate.
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Pentosan Polysulfate.
exisulindexisulind may increase the anticoagulant activities of Pentosan Polysulfate.
FenbufenFenbufen may increase the anticoagulant activities of Pentosan Polysulfate.
FenoprofenFenoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
FibrinolysinFibrinolysin may increase the anticoagulant activities of Pentosan Polysulfate.
FloctafenineFloctafenine may increase the anticoagulant activities of Pentosan Polysulfate.
FlunixinFlunixin may increase the anticoagulant activities of Pentosan Polysulfate.
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Pentosan Polysulfate.
Fondaparinux sodiumPentosan Polysulfate may increase the anticoagulant activities of Fondaparinux sodium.
GenisteinGenistein may decrease the anticoagulant activities of Pentosan Polysulfate.
GestodeneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Gestodene.
HeminHemin may increase the anticoagulant activities of Pentosan Polysulfate.
HeparinPentosan Polysulfate may increase the anticoagulant activities of Heparin.
HexestrolHexestrol may decrease the anticoagulant activities of Pentosan Polysulfate.
HirulogPentosan Polysulfate may increase the anticoagulant activities of Hirulog.
HMPL-004HMPL-004 may increase the anticoagulant activities of Pentosan Polysulfate.
Hydroxyprogesterone caproateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Hydroxyprogesterone caproate.
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibritumomab tiuxetan.
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Pentosan Polysulfate.
IbudilastThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ibudilast.
IbudilastIbudilast may increase the anticoagulant activities of Pentosan Polysulfate.
IbuprofenIbuprofen may increase the anticoagulant activities of Pentosan Polysulfate.
IbuproxamIbuproxam may increase the anticoagulant activities of Pentosan Polysulfate.
IcatibantIcatibant may increase the anticoagulant activities of Pentosan Polysulfate.
Icosapent ethylThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Icosapent ethyl.
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Pentosan Polysulfate.
IfenprodilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ifenprodil.
IfenprodilIfenprodil may increase the anticoagulant activities of Pentosan Polysulfate.
IloprostThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Iloprost.
IloprostIloprost may increase the anticoagulant activities of Pentosan Polysulfate.
IndomethacinIndomethacin may increase the anticoagulant activities of Pentosan Polysulfate.
IndoprofenIndoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
IsoxicamIsoxicam may increase the anticoagulant activities of Pentosan Polysulfate.
KebuzoneKebuzone may increase the anticoagulant activities of Pentosan Polysulfate.
KetoprofenKetoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
KetorolacKetorolac may increase the anticoagulant activities of Pentosan Polysulfate.
LeflunomideLeflunomide may increase the anticoagulant activities of Pentosan Polysulfate.
LepirudinPentosan Polysulfate may increase the anticoagulant activities of Lepirudin.
LevonorgestrelThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Levonorgestrel.
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Pentosan Polysulfate.
LornoxicamLornoxicam may increase the anticoagulant activities of Pentosan Polysulfate.
LoxoprofenLoxoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
LumiracoxibLumiracoxib may increase the anticoagulant activities of Pentosan Polysulfate.
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Pentosan Polysulfate.
MasoprocolMasoprocol may increase the anticoagulant activities of Pentosan Polysulfate.
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.
MedrogestoneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medrogestone.
Medroxyprogesterone acetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Medroxyprogesterone acetate.
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Pentosan Polysulfate.
Megestrol acetateThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Megestrol acetate.
MeloxicamMeloxicam may increase the anticoagulant activities of Pentosan Polysulfate.
MesalazineMesalazine may increase the anticoagulant activities of Pentosan Polysulfate.
MestranolMestranol may decrease the anticoagulant activities of Pentosan Polysulfate.
MetamizoleMetamizole may increase the anticoagulant activities of Pentosan Polysulfate.
MilrinoneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Milrinone.
MilrinoneMilrinone may increase the anticoagulant activities of Pentosan Polysulfate.
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Pentosan Polysulfate.
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Pentosan Polysulfate.
NabumetoneNabumetone may increase the anticoagulant activities of Pentosan Polysulfate.
NadroparinPentosan Polysulfate may increase the anticoagulant activities of Nadroparin.
NaftifineNaftifine may increase the anticoagulant activities of Pentosan Polysulfate.
NaproxenNaproxen may increase the anticoagulant activities of Pentosan Polysulfate.
NCX 4016The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with NCX 4016.
NCX 4016NCX 4016 may increase the anticoagulant activities of Pentosan Polysulfate.
NepafenacNepafenac may increase the anticoagulant activities of Pentosan Polysulfate.
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Pentosan Polysulfate.
NimesulideThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nimesulide.
NimesulideNimesulide may increase the anticoagulant activities of Pentosan Polysulfate.
NintedanibThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Nintedanib.
NorethisteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Norethisterone.
ObinutuzumabThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Obinutuzumab.
OlopatadineOlopatadine may increase the anticoagulant activities of Pentosan Polysulfate.
OlsalazineOlsalazine may increase the anticoagulant activities of Pentosan Polysulfate.
Omacetaxine mepesuccinateThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Omacetaxine mepesuccinate.
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Pentosan Polysulfate.
OrgoteinOrgotein may increase the anticoagulant activities of Pentosan Polysulfate.
OtamixabanPentosan Polysulfate may increase the anticoagulant activities of Otamixaban.
OxaprozinOxaprozin may increase the anticoagulant activities of Pentosan Polysulfate.
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Pentosan Polysulfate.
ParecoxibParecoxib may increase the anticoagulant activities of Pentosan Polysulfate.
ParnaparinParnaparin may increase the anticoagulant activities of Pentosan Polysulfate.
PentoxifyllineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Pentoxifylline.
PentoxifyllinePentoxifylline may increase the anticoagulant activities of Pentosan Polysulfate.
PhenindionePentosan Polysulfate may increase the anticoagulant activities of Phenindione.
PhenprocoumonPentosan Polysulfate may increase the anticoagulant activities of Phenprocoumon.
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Pentosan Polysulfate.
PimecrolimusPimecrolimus may increase the anticoagulant activities of Pentosan Polysulfate.
PirfenidonePirfenidone may increase the anticoagulant activities of Pentosan Polysulfate.
PiroxicamPiroxicam may increase the anticoagulant activities of Pentosan Polysulfate.
PlasminPlasmin may increase the anticoagulant activities of Pentosan Polysulfate.
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Pentosan Polysulfate.
PrasugrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Prasugrel.
PrasugrelPrasugrel may increase the anticoagulant activities of Pentosan Polysulfate.
ProgesteroneThe therapeutic efficacy of Pentosan Polysulfate can be decreased when used in combination with Progesterone.
PropacetamolPropacetamol may increase the anticoagulant activities of Pentosan Polysulfate.
Protein CPentosan Polysulfate may increase the anticoagulant activities of Protein C.
ProtocatechualdehydePentosan Polysulfate may increase the anticoagulant activities of Protocatechualdehyde.
PTC299PTC299 may increase the anticoagulant activities of Pentosan Polysulfate.
QuinestrolQuinestrol may decrease the anticoagulant activities of Pentosan Polysulfate.
ResveratrolThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Resveratrol.
ResveratrolResveratrol may increase the anticoagulant activities of Pentosan Polysulfate.
ReteplaseReteplase may increase the anticoagulant activities of Pentosan Polysulfate.
ReviparinPentosan Polysulfate may increase the anticoagulant activities of Reviparin.
RidogrelThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ridogrel.
RidogrelRidogrel may increase the anticoagulant activities of Pentosan Polysulfate.
RivaroxabanPentosan Polysulfate may increase the anticoagulant activities of Rivaroxaban.
RofecoxibRofecoxib may increase the anticoagulant activities of Pentosan Polysulfate.
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Pentosan Polysulfate.
SalicylamideSalicylamide may increase the anticoagulant activities of Pentosan Polysulfate.
Salicylic acidSalicylic acid may increase the anticoagulant activities of Pentosan Polysulfate.
SalsalateSalsalate may increase the anticoagulant activities of Pentosan Polysulfate.
SCH-530348The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SCH-530348.
SCH-530348SCH-530348 may increase the anticoagulant activities of Pentosan Polysulfate.
SelexipagSelexipag may increase the anticoagulant activities of Pentosan Polysulfate.
SeratrodastSeratrodast may increase the anticoagulant activities of Pentosan Polysulfate.
SevofluraneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Sevoflurane.
SevofluraneSevoflurane may increase the anticoagulant activities of Pentosan Polysulfate.
SRT501The risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with SRT501.
SRT501SRT501 may increase the anticoagulant activities of Pentosan Polysulfate.
StreptokinaseStreptokinase may increase the anticoagulant activities of Pentosan Polysulfate.
SugammadexSugammadex may increase the anticoagulant activities of Pentosan Polysulfate.
SulfasalazineSulfasalazine may increase the anticoagulant activities of Pentosan Polysulfate.
SulindacSulindac may increase the anticoagulant activities of Pentosan Polysulfate.
SulodexidePentosan Polysulfate may increase the anticoagulant activities of Sulodexide.
SuprofenSuprofen may increase the anticoagulant activities of Pentosan Polysulfate.
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Pentosan Polysulfate.
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Pentosan Polysulfate.
TenecteplaseTenecteplase may increase the anticoagulant activities of Pentosan Polysulfate.
TenoxicamTenoxicam may increase the anticoagulant activities of Pentosan Polysulfate.
TepoxalinTepoxalin may increase the anticoagulant activities of Pentosan Polysulfate.
TeriflunomideTeriflunomide may increase the anticoagulant activities of Pentosan Polysulfate.
TesmilifeneThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tesmilifene.
TesmilifeneTesmilifene may increase the anticoagulant activities of Pentosan Polysulfate.
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Pentosan Polysulfate.
TiboloneTibolone may increase the anticoagulant activities of Pentosan Polysulfate.
TicagrelorTicagrelor may increase the anticoagulant activities of Pentosan Polysulfate.
TiclopidineThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Ticlopidine.
TiclopidineTiclopidine may increase the anticoagulant activities of Pentosan Polysulfate.
TinzaparinTinzaparin may increase the anticoagulant activities of Pentosan Polysulfate.
TipranavirTipranavir may increase the anticoagulant activities of Pentosan Polysulfate.
TirofibanThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tirofiban.
TirofibanTirofiban may increase the anticoagulant activities of Pentosan Polysulfate.
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Pentosan Polysulfate.
TolmetinTolmetin may increase the anticoagulant activities of Pentosan Polysulfate.
TositumomabThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tositumomab.
TranilastThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Tranilast.
TranilastTranilast may increase the anticoagulant activities of Pentosan Polysulfate.
TrapidilThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Trapidil.
TrapidilTrapidil may increase the anticoagulant activities of Pentosan Polysulfate.
TreprostinilTreprostinil may increase the anticoagulant activities of Pentosan Polysulfate.
TriflusalThe risk or severity of adverse effects can be increased when Pentosan Polysulfate is combined with Triflusal.
TriflusalTriflusal may increase the anticoagulant activities of Pentosan Polysulfate.
Trisalicylate-cholineTrisalicylate-choline may increase the anticoagulant activities of Pentosan Polysulfate.
UrokinaseUrokinase may increase the anticoagulant activities of Pentosan Polysulfate.
ValdecoxibValdecoxib may increase the anticoagulant activities of Pentosan Polysulfate.
Vitamin EVitamin E may increase the anticoagulant activities of Pentosan Polysulfate.
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Pentosan Polysulfate.
WarfarinPentosan Polysulfate may increase the anticoagulant activities of Warfarin.
XimelagatranPentosan Polysulfate may increase the anticoagulant activities of Ximelagatran.
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Pentosan Polysulfate.
ZeranolZeranol may decrease the anticoagulant activities of Pentosan Polysulfate.
ZileutonZileuton may increase the anticoagulant activities of Pentosan Polysulfate.
ZomepiracZomepirac may increase the anticoagulant activities of Pentosan Polysulfate.
Food Interactions
  • Take on an empty stomach, 1 hour before or 2 hours after meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Ligand-dependent nuclear receptor transcription coactivator activity
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF2
Uniprot ID:
P09038
Molecular Weight:
30769.715 Da
References
  1. Zugmaier G, Favoni R, Jaeger R, Rosen N, Knabbe C: Polysulfated heparinoids selectively inactivate heparin-binding angiogenesis factors. Ann N Y Acad Sci. 1999;886:243-8. [PubMed:10667230 ]
  2. Mucha S, Melen-Mucha G, Stepien T, Godlewski A, Stepien H: Effects of pentosan polysulfate sodium on the estrogen-induced pituitary prolactinoma in Fischer 344 rats. Oncol Rep. 2002 Nov-Dec;9(6):1385-9. [PubMed:12375053 ]
  3. Pluda JM, Shay LE, Foli A, Tannenbaum S, Cohen PJ, Goldspiel BR, Adamo D, Cooper MR, Broder S, Yarchoan R: Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst. 1993 Oct 6;85(19):1585-92. [PubMed:7692072 ]
  4. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat. 1996;39(1):103-17. [PubMed:8738610 ]
  5. Jerebtsova M, Wong E, Przygodzki R, Tang P, Ray PE: A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H743-50. Epub 2006 Oct 27. [PubMed:17071728 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
S100 protein binding
Specific Function:
Plays an important role in the regulation of cell survival, cell division, angiogenesis, cell differentiation and cell migration. Functions as potent mitogen in vitro.
Gene Name:
FGF1
Uniprot ID:
P05230
Molecular Weight:
17459.58 Da
References
  1. Pascu C, Ljungh A, Wadstrom T: Staphylococci bind heparin-binding host growth factors. Curr Microbiol. 1996 Apr;32(4):201-7. [PubMed:8867461 ]
  2. Zenjari C, Boilly-Marer Y, Desbiens X, Oudghir M, Hondermarck H, Boilly B: Experimental evidence for FGF-1 control of blastema cell proliferation during limb regeneration of the amphibian Pleurodeles waltl. Int J Dev Biol. 1996 Oct;40(5):965-71. [PubMed:8946244 ]
  3. Jerebtsova M, Wong E, Przygodzki R, Tang P, Ray PE: A novel role of fibroblast growth factor-2 and pentosan polysulfate in the pathogenesis of intestinal bleeding in mice. Am J Physiol Heart Circ Physiol. 2007 Feb;292(2):H743-50. Epub 2006 Oct 27. [PubMed:17071728 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Heparin binding
Specific Function:
Plays an important role in the regulation of embryonic development, cell proliferation, and cell differentiation. Required for normal limb and cardiac valve development during embryogenesis.
Gene Name:
FGF4
Uniprot ID:
P08620
Molecular Weight:
22047.355 Da
References
  1. Zugmaier G, Lippman ME, Wellstein A: Inhibition by pentosan polysulfate (PPS) of heparin-binding growth factors released from tumor cells and blockage by PPS of tumor growth in animals. J Natl Cancer Inst. 1992 Nov 18;84(22):1716-24. [PubMed:1279186 ]
  2. McLeskey SW, Zhang L, Kharbanda S, Kurebayashi J, Lippman ME, Dickson RB, Kern FG: Fibroblast growth factor overexpressing breast carcinoma cells as models of angiogenesis and metastasis. Breast Cancer Res Treat. 1996;39(1):103-17. [PubMed:8738610 ]
  3. Wellstein A, Zugmaier G, Califano JA 3rd, Kern F, Paik S, Lippman ME: Tumor growth dependent on Kaposi's sarcoma-derived fibroblast growth factor inhibited by pentosan polysulfate. J Natl Cancer Inst. 1991 May 15;83(10):716-20. [PubMed:1708834 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23